2.75
+7.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Editas Medicine
From its filings with the US Securities and Exchange Commission
Editas Medicine is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker EDIT. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $40.5m and a net loss of $160.1m. At that date it held total assets of $186.5m and shareholders' equity of $27.3m.
We are a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome and by harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, gene editing. We believe this progress sets the stage for us to create medicines with the potential to have a durable benefit for patients. Our core capability in gene editing uses the technology known as CRISPR (clustered, regularly interspaced, short palindromic repeats) to allow us to create molecules that efficiently and specifically edit DNA. Our mission is to translate the promise of gene editing into a broad class of differentiated, transformational medicines for previously untreatable diseases.
We have developed a proprietary gene editing platform based on CRISPR technology and we continue to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. Once the complex binds to the DNA sequence it is designed to recognize, the complex makes a specific cut in the DNA. We believe we are the only human gene editing company with a platform that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms of both of these CRISPR systems, and foundational intellectual property for both of these CRISPR systems.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Feb 2016
- Employees
- 87
- Website
- editasmedicine.com ↗
- Head office
- 11 HURLEY ST., CAMBRIDGE, MA, 02141
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Jessica HopfieldIndependent Chairman of the Board$151,303
- Dr. Gilmore O'NeillPresident, Chief Executive Officer, Director, since 2022$5.1m
- Ms. Amy ParisonChief Financial Officer, Senior Vice President, Treasurer
- Dr. Linda BurklyExecutive Vice President, Chief Scientific Officer$1.5m
- Ms. Bernadette ConnaughtonIndependent Director$147,825
- Mr. Andrew HirschIndependent Director$144,075
- Dr. Elliott LevyIndependent Director$140,053
- Dr. David ScaddenIndependent Director$144,782
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 56
- Environment
- 53
- Social
- 99
- Governance
- 15
- Women in the workforce
- 53%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Editas Medicine Inc is equipped with advanced gene editing technology, which allows them to develop innovative therapies and solutions for genetic diseases. This technology provides them with a competitive edge in the market.
- Editas Medicine Inc has a robust intellectual property portfolio, consisting of patents and licenses related to gene editing technology. This protects their inventions and provides a legal barrier for potential competitors.
- Editas Medicine Inc has established strategic partnerships with renowned pharmaceutical companies and academic institutions. These partnerships facilitate collaborative research, access to resources, and potential market expansion opportunities.
Weaknesses
- Editas Medicine Inc currently has a limited product pipeline, which could pose a challenge in terms of revenue generation and growth. They need to actively focus on expanding their portfolio to diversify their offerings.
- Editas Medicine Inc's success is dependent on obtaining regulatory approvals for their gene therapies. Delays or rejections in the approval process could significantly impact their ability to bring products to market and generate revenue.
Opportunities
- The demand for gene therapies is on the rise, presenting Editas Medicine Inc with an opportunity to address unmet medical needs and capitalize on a growing market. They can leverage their technology to develop effective treatments for various genetic disorders.
- Editas Medicine Inc can explore opportunities in emerging markets, where access to advanced medical treatments might be limited. By expanding their presence in such markets, they can reach a wider patient population and increase their market share.
Threats
- Editas Medicine Inc faces competition from established pharmaceutical companies that have their own gene editing technologies. This competitive landscape can pose challenges in terms of market share, pricing, and customer adoption.
- The gene editing industry is subject to strict regulations and ethical considerations. Editas Medicine Inc needs to navigate these challenges and ensure their operations and products adhere to legal and ethical frameworks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.